Insulin glargine, a long-acting insulin analog, is essential for managing diabetes mellitus by offering stable glucose control for up to 24 hours. With the increasing global prevalence of diabetes, biosimilars of insulin glargine have emerged as a cost-effective alternative to branded options like Sanofi's Lantus, alleviating the financial strain o